On November 16, 2017 Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), reported that John P. Butler, President and Chief Executive Officer, will participate in the following investor conferences(Press release, Akebia, NOV 16, 2017, View Source [SID1234522110]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 29th Annual Piper Jaffray Healthcare Conference on Wednesday, November 29, 2017, at 12:30 p.m. Eastern Time, to be held at the Lotte New York Palace in New York, NY.
The Evercore ISI Biopharma Catalyst/Deep Dive Conference on Thursday, November 30, 2017, at 9:30 a.m. Eastern Time, to be held at the Boston Harbor Hotel in Boston, MA.
The Global Mizuho Investor Conference on Tuesday, December 5, 2017, to be held at the Lotte New York Palace in New York, NY.
A live audio webcast from the presentation at Piper Jaffray and fireside chat at Evercore will be available on the Company’s website at View Source, with archives available for 90 days.